TABLE 2.
Results and calculation of specificity and sensitivity of HIV antibody EIAs with samples from hospitalized patients and blood donors
| Assay | No. of samples with result
|
% Sensitivity | % Specificity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitalized patientsa
|
Blood donors
|
|||||||||||
| Positive | Negative | False positive | False negative | Total | Positive | Negative | False positive | False negative | Total | |||
| Enzymun-Test Anti-HIV 1 + 2 + Subtyp O | 1,887 | 5,332 | 10 | 0 | 7,219 | 3 | 3,950 | 9 | 0 | 3,953 | 100 | 99.8 |
| Abbott Recomb. HIV-1/HIV-2 3rd Gen. EIA | 257 | 491 | 29 | 0 | 748 | 0 | 190 | 1 | 0 | 191 | 100 | 95.8 |
| Abbott HIV-1/HIV-2 3rd Gen. Plus EIA | 134 | 618 | 4 | 0 | 752 | 0 | 153 | 0 | 0 | 153 | 100 | 99.5 |
| IMx HIV-1/HIV-2 3rd Gen. | 275 | 910 | 3 | 0 | 1,185 | 0 | 0 | 0 | 0 | 0 | 100 | 99.7 |
| IMx HIV-1/HIV-2 3rd Gen. Plus | 113 | 457 | 0 | 0 | 570 | 0 | 0 | 0 | 0 | 0 | 100 | 100 |
| Axsym HIV-1/HIV-2 | 47 | 411 | 0 | 0 | 458 | 0 | 0 | 0 | 0 | 0 | 100 | 100 |
| Enzygnost Anti-HIV 1/2 Plus | 199 | 467 | 0 | 0 | 666 | 2 | 158 | 0 | 0 | 160 | 100 | 100 |
| Wellcozyme HIV Recombinant | 157 | 506 | 19 | 0 | 663 | 0 | 234 | 1 | 0 | 234 | 100 | 97.4 |
| Genelavia Mixt | 153 | 308 | 4 | 0 | 461 | 0 | 225 | 0 | 0 | 225 | 99.3 | 100 |
a
These samples include 268 potentially interfering samples obtained from patients with autoimmune diseases (n = 116), patients who are rheumatoid factor positive (n = 35), and patients with acute viral illness caused by cytomegalovirus (n = 24), Epstein-Barr virus (n = 7), hepatitis B (n = 26) and C (n = 40) viruses, and human T-cell leukemia virus type 1 (n = 20).